Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Irish Journal of Medical Science (1971 -)
Erschienen in: Irish Journal of Medical Science (1971 -) 2/2020

11.11.2019 | Review Article

Current role of the collagenase Clostridium histolyticum in Dupuytren’s disease treatment

verfasst von: Rafael Sanjuan-Cervero

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Collagenase Clostridium histolyticum (CCH) is a recent treatment for Dupuytren disease, which is a fibroproliferative disorder that leads to progressive, persistent digital flexion contracture that interferes with basic daily activities. While CCH has changed the treatment of this hand disorder, numerous concerns have to be analyzed.

Aims

Our purpose is to assess the current status of this medical treatment.

Methods

Literary review based on a manual search on PubMed, Web of Science, and Google Academic.

Results

Pharmacoeconomic analyses support the use of CCH, but long-term studies showing that it should be favored over conventional surgery or other treatments are lacking. Treatment decisions, therefore, must be guided by current data, which include a 5-year recurrence rate of 47%. Complications following CCH treatment are also a controversial topic, as rates of over 90% have been reported, although most of the complications are mild and self-limiting. A definition and classification of CCH-related complications is sorely needed. If we exclude adverse effects that could be considered inherent to the mechanisms of action of CCH, then the complication rate would be similar to rates reported for other techniques. Although CCH is becoming an increasingly popular treatment for Dupuytren disease, the potential applications of this modality, are much higher than currently believed, for more disorders characterized by excessive fibrosis.

Conclusion

Currently, the administration of this treatment is promising although long-term studies are necessary to see the real role that this drug can play in both Dupuytren’s disease and other fibrotic disorders.
Literatur
1.
Dibenedetti DB, Nguyen D, Zografos L et al (2011) Prevalence, incidence, and treatments of Dupuytren’s disease in the United States: results from a population-based study. Hand N Y N 6:149–158
2.
Shih B, Watson S, Bayat A (2012) Whole genome and global expression profiling of Dupuytren’s disease: systematic review of current findings and future perspectives. Ann Rheum Dis 71:1440–1447PubMed
3.
Brickley-Parsons D, Glimcher MJ, Smith RJ et al (1981) Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren’s disease. J Bone Jt Surg Am 63:787–797
4.
Hinz B, Phan SH, Thannickal VJ et al (2007) The myofibroblast: one function, multiple origins. Am J Pathol 170:1807–1816PubMedPubMedCentral
5.
Hueston JI (1992) Lessons in Dupuytren’s disease. Ann Chir Main Memb Supér 11:349–354PubMed
6.
Clarkson P (1963) The radical fasciectomy operation for Dupuytren’s disease: a condemnation. Br J Plast Surg 16:273–279PubMed
7.
Lermusiaux J-L, Badois F, Lellouche H (2001) Maladie de Dupuytren. Rev Rhum 68:542–547
8.
Dias J, Bainbridge C, Leclercq C et al (2013) Surgical management of Dupuytren’s contracture in Europe: regional analysis of a surgeon survey and patient chart review. Int J Clin Pract 67:271–281PubMed
9.
Duarte AS, Correia A, Esteves AC (2016) Bacterial collagenases - a review. Crit Rev Microbiol 42:106–126PubMed
10.
11.
Hoogerheide JC (1937) Variability in morphological and biochemical properties of Clostridium histolyticum (Weinberg and Seguin). J Bacteriol 34:387–407PubMedPubMedCentral
12.
Bond MD, Van Wart HE (1984) Characterization of the individual collagenases from Clostridium histolyticum. Biochemistry 23:3085–3091PubMed
13.
Bond MD, Van Wart HE (1984) Purification and separation of individual collagenases of Clostridium histolyticum using red dye ligand chromatography. Biochemistry 23:3077–3085PubMed
14.
Bond MD, Van Wart HE (1984) Relationship between the individual collagenases of Clostridium histolyticum: evidence for evolution by gene duplication. Biochemistry 23:3092–3099PubMed
15.
Sanjuan-Cerveró R, Gomez-Herrero D, Carrera-Hueso FJ (2016) Mechanism of action of collagenase clostridium histolyticum for clinical application. Eur J Clin Pharm Aten Farm 18:8–8
16.
Bromley JW, Hirst JW, Osman M, Steinlauf P, Gennace RE, Stern H (1980) Collagenase: an experimental study of intervertebral disc dissolution. Spine 5:126–132PubMed
17.
Gelbard MK, Walsh R, Kaufman JJ (1982) Collagenase for Peyronie’s disease experimental studies. Urol Res 10:135–140PubMed
18.
Badalamente MA, Hurst LC Collagenase: preclinical evaluation and clinical trials in the USA and Australia. In: Collagenase in Dupuytren Disease. Springer, Cham, pp 7–16
19.
Badalamente MA, Hurst LC (2018) Development of collagenase treatment for Dupuytren disease. Hand Clin 34:345–349PubMed
20.
Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FT, Meals RA, Smith TM, Rodzvilla J, CORD I Study Group (2009) Injectable collagenase Clostridium histolyticum for Dupuytren’s contracture. N Engl J Med 361:968–979PubMed
21.
Gilpin D, Coleman S, Hall S et al (2010) Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg 35:2027-2038.e1
22.
Peimer CA, Skodny P, Mackowiak JI (2013) Collagenase Clostridium histolyticum for Dupuytren contracture: patterns of use and effectiveness in clinical practice. J Hand Surg 38:2370–2376
23.
Peimer CA, Blazar P, Coleman S et al (2015) Dupuytren contracture recurrence following treatment with collagenase Clostridium histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-year data. J Hand Surg 40:1597–1605
24.
Warwick D, Arner M, Pajardi G et al (2015) Collagenase clostridium histolyticum in patients with Dupuytren’s contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes. J Hand Surg Eur Vol 40:124–132PubMedPubMedCentral
25.
Hirata H, Tanaka K, Sakai A et al (2016) Efficacy and safety of collagenase Clostridium histolyticum injection for Dupuytren’s contracture in non-Caucasian Japanese patients (CORD-J Study): the first clinical trial in a non-Caucasian population. J Hand Surg Eur Vol 42:30–38PubMed
26.
Bebbington E, Furniss D (2015) Linear regression analysis of Hospital Episode Statistics predicts a large increase in demand for elective hand surgery in England. J Plast Reconstr Aesthet Surg 68:243–251PubMedPubMedCentral
27.
Chen NC, Shauver MJ, Chung KC (2011) Cost-effectiveness of open partial fasciectomy, needle aponeurotomy, and collagenase injection for Dupuytren contracture. J Hand Surg 36:1826-1834.e32
28.
Malone DC, Armstrong EP (2012) PMS29 Cost-Effectiveness of collagenase Clostridium histolyticum, limited fasciectomy, and percutaneous needle fasciotomy in the treatment of Dupuytren’s contracture. Value Health 15:A38–A39
29.
Baltzer H, Binhammer PA (2013) Cost-effectiveness in the management of Dupuytren’s contracture a Canadian cost-utility analysis of current and future management strategies. Bone Jt J 95-B:1094–1100
30.
Sanjuan-Cervero R, Franco-Ferrando N, Poquet-Jornet JE et al Short-term cost-utility analysis of collagenase versus fasciectomy for Dupuytren contracture. In: Dupuytren Disease and Related Diseases - The Cutting Edge. Springer, Cham, pp 271–275
31.
Murphy LE, Murphy KM, Kilpatrick SM et al (2017) The use of collagenase Clostridium histolyticum in the management of Dupuytren’s contracture-outcomes of a pilot study in a district general hospital setting. Ulst Med J 86:94–98
32.
Dritsaki M, Rivero-Arias O, Gray A et al (2018) What do we know about managing Dupuytren’s disease cost-effectively? BMC Musculoskelet Disord 19:34PubMedPubMedCentral
33.
Sanjuan-Cerveró R, Franco-Ferrando N, Poquet-Jornet J (2013) Use of resources and costs associated with the treatment of Dupuytren’s contracture at an orthopedics and traumatology surgery department in Denia (Spain): collagenase clostridium hystolyticum versus subtotal fasciectomy. BMC Musculoskelet Disord 14:293PubMedPubMedCentral
34.
Leskelä R-L, Herse F, Torkki P et al (2016) Analysis of the adoption of new health technology: the case of Dupuytren’s disease. Int J Healthc Technol Manag 15:210–227
35.
Sanjuan-Cerveró R, Vazquez-Ferreiro P, Gomez-Herrero D et al (2017) Efficacy of collagenase Clostridium histolyticum for Dupuytren disease: a systematic review. Rev Iberoam Cir Mano 45:070–088
36.
Warwick D Collagenase: what we may never know (a discussion). In: PMN W, Dias J, Eaton C et al (eds) Dupuytren Disease and Related Diseases - The Cutting Edge. Springer International Publishing, pp 145–149
37.
Jupiter J, Burke D (2013) Scott’s parabola and the rise of the medical–industrial complex. Hand N Y N 8:249–252
38.
Scott JW (2001) Scott’s parabola. BMJ 323:1477
39.
Arandes-Renú JM, Sanjuán-Cerveró R, Moya-Molinas I Collagenase in Europe from the experimental phase to practical use. In: Pajardi G, Badalamente MA, Hurst LC (eds) Collagenase in Dupuytren Disease. Springer International Publishing, Cham, pp 39–74
40.
Sanjuan-Cerveró R, Carrera-Hueso FJ, Vazquez-Ferreiro P et al (2017) Adverse effects of collagenase in the treatment of Dupuytren disease: a systematic review. BioDrugs Clin Immunother Biopharm Gene Ther 31:105–115
41.
Peimer CA, Wilbrand S, Gerber RA et al (2015) Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren’s contracture. J Hand Surg Eur Vol 40:141–149PubMedPubMedCentral
42.
Lewallen LW, Rizzo M (2017) Phalangeal fracture during attempted Dupuytrens release following clostridial collagenase injection: case report. J Orthop Case Rep 7:21–24PubMedPubMedCentral
43.
Sanjuan-Cerveró R, Franco N (2014) Vasospasm after collagenase Clostridium histolyticum infiltration in Dupuytren’s contracture. Int J Med Pharm Case Rep 1:42–48
44.
Wozniczka J, Canepa C, Mirarchi A et al (2017) Complications following collagenase treatment for Dupuytren contracture. HAND 1558944717711461
45.
Eaton C Controversy: the contracture in Dupuytren disease is a passive process. In: Werker PMN, Dias J, Eaton C et al (eds) Dupuytren Disease and Related Diseases - The Cutting Edge. Springer International Publishing, pp 89–96
46.
Hurst L Dupuytre's contracture. In: Green’s Operative Hand Surgery. Churchill Livingstone, Edimburg, pp 141–158
47.
Hohendorff B, Spies CK, Müller LP, Ries C (2016) Supplementary arthrolysis of the proximal interphalangeal finger joint in Dupuytren’s contracture: primary operation versus revision. Arch Orthop Trauma Surg 136:435–439PubMed
48.
Sanjuan-Cerveró R, Carrera-Hueso FJ, Vazquez-Ferreiro P et al (2018) Efficacy and adverse effects of collagenase use in the treatment of Dupuytren’s disease: a meta-analysis. Bone Jt J 100-B:73–80
49.
Peimer CA, Blazar P, Coleman S et al (2013) Dupuytren contracture recurrence following treatment with collagenase Clostridium histolyticum (CORDLESS Study): 3-year data. J Hand Surg 38:12–22
50.
Warwick D (2017) Dupuytren’s disease: my personal view. J Hand Surg Eur Vol 42:665–672PubMed
51.
Wilbrand S Collagenase: future perspectives. In: Pajardi G, Badalamente MA, Hurst LC (eds) Collagenase in Dupuytren Disease. Springer International Publishing, Cham, pp 131–142
52.
Hutchinson JW, Tierney GM, Parsons SL et al (1998) Dupuytren’s disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg Br 80-B:907–908
53.
54.
55.
Fischer S, Diehm Y, Henzler T, Berger MR, Kolbenschlag J, Latz A, Bueno EM, Hirche C, Kneser U, Pomahac B (2017) Long-Term Effects of the Collagenase of the Bacterium Clostridium histolyticum for the Treatment of Capsular Fibrosis After Silicone Implants. Aesthetic Plast Surg 41:211–220PubMed
56.
57.
Varga J, Pasche B (2008) Anti-TGF-ß Therapy in Fibrosis: recent progress and implications for systemic sclerosis. Curr Opin Rheumatol 20:720–728PubMedPubMedCentral
58.
Zhou C, Liu F, Gallo PH et al (2016) Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts. BMC Musculoskelet Disord 17:469PubMedPubMedCentral
59.
60.
Pan A, Wang Z, Chen B, Dai W, Zhang H, He B, Wang X, Wang Y, Zhang Q (2018) Localized co-delivery of collagenase and trastuzumab by thermosensitive hydrogels for enhanced antitumor efficacy in human breast xenograft. Drug Deliv 25:1495–1503PubMedPubMedCentral
Metadaten
Titel
Current role of the collagenase Clostridium histolyticum in Dupuytren’s disease treatment
verfasst von
Rafael Sanjuan-Cervero
Publikationsdatum
11.11.2019
Verlag
Springer London
Erschienen in
Irish Journal of Medical Science (1971 -) / Ausgabe 2/2020
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-019-02127-z

Weitere Artikel der Ausgabe 2/2020

Irish Journal of Medical Science (1971 -) 2/2020 Zur Ausgabe

Original Article

Clinical outcomes of patients with pure small cell carcinoma of the urinary bladder

Original Article

Effects of low-temperature plasma treatment on pulmonary function in children with obstructive sleep apnea-hypopnea syndrome

Original Article

The effect of spinal manipulation on brain neurometabolites in chronic nonspecific low back pain patients: a randomized clinical trial

Review Article

Systematic review of pleural-amniotic shunt insertion vs. conservative management in isolated bilateral fetal hydrothorax without hydrops

Original Article

Pharmacokinetic enhancers (cobicistat/ritonavir) and the potential for drug-drug interactions

Letter to the Editor

The role of speckle tracking echocardiography in monitoring cardiac function in patients with hereditary hemochromatosis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise